Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20134953 | 0.88 | PIK3CA (0.47) | PIK3CAPIK3R1USP30GPR119KDM4E | |
| SCHEMBL23761149 | 0.83 | PIK3CA (0.44) | PIK3CAPIK3R1FNTAFNTBUSP30 | |
| SCHEMBL26506272 | 0.83 | PIK3CA (0.44) | PIK3CAPIK3R1FNTAFNTBUSP30 | |
| SCHEMBL28644146 | 0.82 | USP30 (0.45) | FNTAFNTBUSP30IDO1TDO2 | |
| SCHEMBL28644150 | 0.82 | USP30 (0.45) | FNTAFNTBUSP30IDO1TDO2 | |
| SCHEMBL20134832 | 0.81 | GPR119 (0.48) | PIK3CAPIK3R1FNTAFNTBUSP30 | |
| SCHEMBL4106892 | 0.81 | FPR2 (0.46) | USP30FPR2GPR119KDM4EMAPT | |
| SCHEMBL25150910 | 0.78 | USP30 (0.42) | PIK3CAUSP30FPR2IDO1TDO2 | |
| SCHEMBL30400063 | 0.78 | USP30 (0.42) | PIK3CAUSP30FPR2IDO1TDO2 | |
| SCHEMBL2964825 | 0.77 | CYP11B2 (0.42) | FNTAFNTBUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | PIK3CA 3049/4885PIK3R1 2023/4885FNTA 3395/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | PIK3CA 3145/4885PIK3R1 2393/4885FNTA 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.